Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Interleukin-23 (IL-23) has emerged as a new therapeutic target for the treatment of inflammatory bowel disease (IBD). As biomarkers of disease state and treatment efficacy are becoming increasingly important in drug development, we sought to identify efficacy biomarkers for anti-IL-23 therapy in Crohn's disease (CD). METHODS: Candidate IL-23 biomarkers, downstream of IL-23 signaling, were identified using shotgun proteomic analysis of feces and colon lavages obtained from a short-term mouse IBD model (anti-CD40 Rag2(-/-)) treated preventively with monoclonal antibodies (mAbs) to the IL-23 receptor (IL-23R). The biomarkers were then measured in an IBD T-cell transfer model treated therapeutically with a mAb to IL-23 (p19), confirming their association with IBD. To assess the clinical relevance of these markers, we assessed their concentrations in clinical serum, colon tissue, and feces from CD patients. RESULTS: We identified 57 proteins up or downregulated in diseased animals that returned to control values when the mice were treated with mAbs to IL-23R. Among those, S100A8, S100A9, regenerating protein 3β (REG), REG3γ, lipocalin 2 (LCN2), deleted in malignant tumor 1 (DMBT1), and macrophage migration inhibitory factor (MIF) mRNA levels correlated with disease score and dose titration of mAbs to IL-23R or IL-23(p19). All biomarkers, except DMBT1, were also downregulated after therapeutic administration of mAbs to IL-23(p19) in a T-cell transfer IBD mouse model. In sera from CD patients, we confirmed a significant upregulation of S100A8/A9 (43%), MIF (138%), pancreatitis-associated protein (PAP, human homolog of REG3β/γ; 49%), LCN2 (520%), and CCL20 (1280%), compared with control samples, as well as a significant upregulation of S100A8/A9 (887%), PAP (401%), and LCN2 (783%) in human feces from CD patients compared with normal controls. CONCLUSIONS: These studies identify multiple protein biomarkers downstream of IL-23 that could be valuable tools to assess the efficacy of this new therapeutic agent.Clinical and Translational Gastroenterology (2012) 3, e10; doi:10.1038/ctg.2012.2; published online 16 February 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Increased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing
Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., Lehr, H.-A., Hirth, S., Weigmann, B., Wirtz, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082683 · Cited by 1,043 · cited 1×
“Notably, REG protein expression in the colon is IL-22 dependent through STAT3 signaling.(37,38) Moreover, STAT3 and other downstream mediators of IL-23R such as JAK2 have been identified as CD susceptibility genes.”
Interleukin-23 drives innate and T cell–mediated intestinal inflammation
Hue, S., Ahern, P., Buonocore, S., Kullberg, M. C., Cua, D. J., McKenzie, B. S., Powrie, F., & Maloy, K. J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061099 · Cited by 823
Self-citationDual Action of Neutrophil Gelatinase–Associated Lipocalin
Schmidt-Ott, K. M., Mori, K., Li, J. Y., Kalandadze, A., Cohen, D. J., Devarajan, P., & Barasch, J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080882 · Cited by 772 · cited 1×
“LCN2, another antimicrobial protein expressed by immune cells and colonic epithelial cells, exerts a bacteriostatic effect by sequestering small iron-binding molecules synthesized by bacteria as a mean of iron acquisition.(40) LCN2 overexpression is part of an IBD-specific gene signature established in patient gut bio…”
Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice
Elson, C. O., Cong, Y., Weaver, C. T., Schoeb, T. R., McClanahan, T. K., Fick, R. B., & Kastelein, R. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.104 · Cited by 453 · cited 2×
“As T cells are also involved in human disease, we assessed the validity of the candidate biomarkers in the T-cell-dependent colitis mouse model established by Elson et al.6 In these mice, adoptive transfer of Bir14 CD4þ T cells to SCID recipients, colitis is established over several weeks, allowing us to evaluate cand…”
Self-citationThe State of Innovation in Drug Development
Kola, I. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100479 · Cited by 276 · cited 2×
“Because of this, objective and robust target-engagement biomarker confirming that the drug has bound its target in a functional manner, and efficacy biomarkers to guide the drug-dose selection in clinical trials have become an integral part of drug development.(14) The most attractive target engagement and efficacy bi…”
Cited by
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Self-citationSands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.049 · Cited by 279
IL-23 in inflammatory bowel diseases and colon cancer
Neurath, M. F. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.12.002 · Cited by 214
Transition metal ions at the crossroads of mucosal immunity and microbial pathogenesis
Diaz-Ochoa, V. E., Jellbauer, S., Klaus, S., & Raffatellu, M. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00002 · Cited by 129
Toyonaga, T., Matsuura, M., Mori, K., Honzawa, Y., Minami, N., Yamada, S., Kobayashi, T., Hibi, T., & Nakase, H. (2016) · Scientific Reports · doi:10.1038/srep35014 · Cited by 75
Kortman, G. A. M., Mulder, M. L. M., Richters, T. J. W., Shanmugam, N. K. N., Trebicka, E., Boekhorst, J., Timmerman, H. M., Roelofs, R., Wiegerinck, E. T., Laarakkers, C. M., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545642 · Cited by 65
Metadata
- Authors
- Cayatte, C., Joyce-Shaikh, B., Vega, F., Boniface, K., Grein, J., Murphy, E., Blumenschein, W. M., Chen, S., Malinao, M.-C., Basham, B., Pierce, R. H., Bowman, E. P., McKenzie, B. S., Elson, C. O., Faubion, W. A., de Waal Malefyt, R., Kastelein, R. A., Cua, D., McClanahan, T. K., & Beaumont, M.
- Venue
- Clinical and Translational Gastroenterology
- Published
- 2012-02
- Volume
- 3
- Issue
- 2
- Pages
- e10
- ISSN
- 2155-384X (ISSN-L)
- OpenAlex
- W2100273400
- Cited by
- 52
- References
- 7
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.